Research article Special Issues

Visit Patterns for Severe Mental Illness with Implementation of Integrated Care: A Pilot Retrospective Cohort Study

  • There is increasing interest in models that integrate behavioral health services into primary care. For patients with severe mental illness (SMI), a population with disproportionate morbidity and mortality, little is known about the impact of such models on primary care clinic utilization, and provider panels. We performed a retrospective cohort pilot study examining visit patterns for 1,105 patients with SMI overall, by provider, before, and after the implementation of a primary care behavioral health model which had a ramp up period from May 2006-August 2007. We used 2003-2012 electronic health record data from two clinics of a Federally Qualified Health Center and conducted interrupted time series and chi-square analyses. During the intervention period there was a significant increase in the proportion of visits per month to the clinic for patient with SMI relative to overall visits (0.27; 95% CI 0.22-0.32). After the intervention period, this rate declined (-0.23; -0.19-0.28) but remained above the pre-intervention period. After integration of behavioral health into our primary care clinics, there was a sharp increase in the number of patients with SMI, suggesting patient willingness to explore receiving care under this model. Clinics looking to adopt the model should be mindful of potential changes in patient subpopulations and proactively manage this transition.

    Citation: Meghan Fondow, Nancy Pandhi, Jason Ricco, Elizabeth Zeidler Schreiter, Lauren Fahey, Neftali Serrano, Marguerite Burns, Elizabeth A. Jacobs. Visit Patterns for Severe Mental Illness with Implementation of Integrated Care: A Pilot Retrospective Cohort Study[J]. AIMS Public Health, 2015, 2(4): 821-831. doi: 10.3934/publichealth.2015.4.821

    Related Papers:

    [1] Bethany M. Kwan, Aimee B. Valeras, Shandra Brown Levey, Donald E. Nease, Mary E. Talen . An Evidence Roadmap for Implementation of Integrated Behavioral Health under the Affordable Care Act. AIMS Public Health, 2015, 2(4): 691-717. doi: 10.3934/publichealth.2015.4.691
    [2] Andrea M. Auxier, Bonni D. Hopkins, Anne E. Reins . Under Construction: One States Approach to Creating Health Homes for Individuals with Serious Mental Illness. AIMS Public Health, 2015, 2(2): 163-182. doi: 10.3934/publichealth.2015.2.163
    [3] Tyler C. Smith MS PhD, Besa Smith MPH PhD . Understanding the Early Signs of Chronic Disease by Investigating the Overlap of Mental Health Needs and Adolescent Obesity. AIMS Public Health, 2015, 2(3): 487-500. doi: 10.3934/publichealth.2015.3.487
    [4] Elham Hatef, Zachary Predmore, Elyse C. Lasser, Hadi Kharrazi, Karin Nelson, Idamay Curtis, Stephan Fihn, Jonathan P. Weiner . Integrating social and behavioral determinants of health into patient care and population health at Veterans Health Administration: a conceptual framework and an assessment of available individual and population level data sources and evidence-based measurements. AIMS Public Health, 2019, 6(3): 209-224. doi: 10.3934/publichealth.2019.3.209
    [5] LauraM.Daniels, KimE.Dixon, LisaC.Campbell . Building Capacity for Behavioral Health Services and Clinical Research in a Rural Primary Care Clinic: A Case Study. AIMS Public Health, 2014, 1(2): 60-75. doi: 10.3934/publichealth.2014.2.60
    [6] Giovanni Napoli, Simone Autuori, Kumi Senkyire Ephraim . Attitudes of Italian mental health nurses towards mental illness and recovery: a cross-sectional study. AIMS Public Health, 2023, 10(2): 333-347. doi: 10.3934/publichealth.2023025
    [7] Larrell L. Wilkinson, Saundra H. Glover, Janice C. Probst, Bo Cai, Lisa T. Wigfall . Psychological Distress and Health Insurance Coverage among Formerly Incarcerated Young Adults in the United States. AIMS Public Health, 2015, 2(3): 227-246. doi: 10.3934/publichealth.2015.3.227
    [8] Elizabeth Burner, Sophie Terp, Chun Nok Lam, Emily Neill, Michael Menchine, Sanjay Arora . Access to care, nativity and disease management among Latinos with diabetes in a safety-net healthcare setting. AIMS Public Health, 2019, 6(4): 488-501. doi: 10.3934/publichealth.2019.4.488
    [9] Abdulqadir J. Nashwan, Rejo G. Mathew, Reni Anil, Nabeel F. Allobaney, Sindhumole Krishnan Nair, Ahmed S. Mohamed, Ahmad A. Abujaber, Abbas Balouchi, Evangelos C. Fradelos . The safety, health, and well-being of healthcare workers during COVID-19: A scoping review. AIMS Public Health, 2023, 10(3): 593-609. doi: 10.3934/publichealth.2023042
    [10] Allison B. Reiss, Donna de Levante Raphael, Nathaniel A. Chin, Vivek Sinha . The physician's Alzheimer's disease management guide: Early detection and diagnosis of cognitive impairment, Alzheimer's disease and related dementia. AIMS Public Health, 2022, 9(4): 661-689. doi: 10.3934/publichealth.2022047
  • There is increasing interest in models that integrate behavioral health services into primary care. For patients with severe mental illness (SMI), a population with disproportionate morbidity and mortality, little is known about the impact of such models on primary care clinic utilization, and provider panels. We performed a retrospective cohort pilot study examining visit patterns for 1,105 patients with SMI overall, by provider, before, and after the implementation of a primary care behavioral health model which had a ramp up period from May 2006-August 2007. We used 2003-2012 electronic health record data from two clinics of a Federally Qualified Health Center and conducted interrupted time series and chi-square analyses. During the intervention period there was a significant increase in the proportion of visits per month to the clinic for patient with SMI relative to overall visits (0.27; 95% CI 0.22-0.32). After the intervention period, this rate declined (-0.23; -0.19-0.28) but remained above the pre-intervention period. After integration of behavioral health into our primary care clinics, there was a sharp increase in the number of patients with SMI, suggesting patient willingness to explore receiving care under this model. Clinics looking to adopt the model should be mindful of potential changes in patient subpopulations and proactively manage this transition.


    1. Introduction

    With the growing understanding of the importance of a proper magnesium homeostasis during pregnancy, an increasing number of studies have used magnesium for treatment or prevention of different pathological conditions in pregnancy. The aims of the review is to describe the major studies performed on treatment with magnesium in pregnancy related complications. The studies reviewed were collected from a previous Cochrane review with differences in the criteria for the evaluation of the relevance of the studies [1].

    2. Treatment

    Based in the knowledge regarding the pivotal role of magnesium in enzyme systems, muscular function and bone calcium homeostasis [2], a large number of studies has been reported on the treatment of different pathological conditions with magnesium. Regarding pregnancy, the treatment of pre-eclampsia and eclampsia with MgSO4 is an established procedure. The treatment is initiated on suspicion of eclampsia or when the symptoms are fully established. It comprises an intravenous injection (usually 4-6 g), followed by sometimes followed by a maintenance dose given intravenously or intramuscularly. Side effects are nausea, flushing, and muscle weakness. A Cochrane review evaluated 13 studies, one of which comprised 10^141 women [3]. In general the treatment was found to be efficient in about half the cases. Similar findings were reported in a review comprising studies from Bangladesh, India, Pakistan, Nigeria, and the UK [4].

    The initial concept for introducing MgSO4 in the treatment of eclampsia and pre-eclampsia was as an anticonvulsive agent, as the anti-cramp properties of this agent (Epsom salt) have been known since the 1600th century. Recent data suggest that the effect may be mediated through prevention of oxidative damage through interactions with alkyl radicals [5]. A study on pregnant women from Sub-Saharan Africa evaluated the role of MgSO4 treatment and increased use of transfers to hospitals [6]. About 17000 maternal deaths were associated with PE/E. A more extensive use of MgSO4 would have prevented 610 deaths.

    In addition to treatment of pre-eclampsia and eclampsia, MgSO4 has also been used in attempts to protect the children from neurological disorders as reviewed in two meta-analysis [7,8]. One study found a reduction of hypotension treatment and invasive mechanical ventilation in pre-term infants treated with MgSO4 [9].

    3. Prevention

    In addition to treating an established or almost established disease, several studies have attempted to avoid the development of disease by giving magnesium as a supplement during the whole pregnancy. The rationale for this is the many reports that describe an insufficient supply of magnesium in the food intake among pregnant women [10,11,12].

    The conductance and interpretation of results from such magnesium supplementation studies in populations may be influenced by a number of methodological problems [13]. An effect of the supplementation can only be expected in a risk group i.e. persons with a magnesium deficiency. The proportion of such risk persons in the population studied or differences in that proportion between different population groups would thus influence the results. Evaluating the effect in the whole population studied without identifying the risk group might thus lead to a false conclusion concerning the absence of an effect.

    The therapeutic range is of importance. Some earlier studies used low doses of magnesium in the supplementation—128 mg [14]. Another study administered magnesium (100 mg) also to the control group, yielding a therapeutic range of 270 mg [15]. This is relatively low in comparison to the 300-400 mg doses usually used. The lower dose administered to the control group—100 mg— might also have been sufficient to reduce a negative effect induced by magnesium deficiency.

    3.1. Prevention—blood pressure

    Several studies have investigated the possibility to prevent the pregnancy induced high increase in blood pressure, including pre-eclampsia and eclampsia, during pregnancy by giving a supplementation of magnesium throughout pregnancy. In a double blind, randomised controlled (DBRC) study in Denmark, 50 women with a pregnancy induced hypertension were given intravenous magnesium chloride for two days and then an oral supply of magnesium hydroxide till the end of the pregnancy [16]. In the supplemented group, mean atrial blood pressure was significantly lower from day three of supplementation till delivery.

    In a DBRC study from China, 51 pregnant women were given 175 mg magnesium gluconate daily [17]. In the supplemented group 4% of the women developed hypertension as compared to 16% in the placebo group. In a partial DBRC study from Angola 150 pregnant women were given primrose and fish oil, magnesium oxide or placebo [18]. In the magnesium group there were two women with high blood pressure (systolic >30 and/or diastolic > 15 mm Hg) as compared to 13 in the untreated group.

    In a DBRC study from Sweden, prima-para subjects were given 300 mg magnesium as a citrate salt or placebo from around pregnancy week 25 throughout the pregnancy [19]. The changes in diastolic blood pressure at different times during the pregnancy in relation to the value at 12 weeks were evaluated and magnesium sensitive transporter gene (MgTG) expressions were measured [20]. The percentage of women with an increase of ≥15 mm Hg in diastolic blood pressure was significantly lower in the magnesium supplemented group. Among those with an increase in urinary magnesium excretion during pregnancy, reflecting the increased intake, there was a decrease in the diastolic blood pressure (corr coeff -0.438, p = 0.005). Systolic and diastolic blood pressures at week 37 (excluding the magnesium treated group) were significantly related to the expression of the MgTGs SLC41A1 and SLC41A3. In week 12 as well as in week 37, the expression of TRPM6 was significantly higher as compared to a group of non-pregnant subjects (p = 0.007). In the placebo group the expression of gene TRPM6 was significantly higher among those with an increase in diastolic blood pressure ≥15 mm Hg (0.84/0.07 vs. 0.64/0.04, p = 0.013). There was also an inverse relationship between the expression of TRPM6 and the urinary excretion of magnesium (corr coeff -0.596, p = 0.015).

    One study could not demonstrate an effect of magnesium- aspartate hydrochloride on high blood pressure [15]. This was not, however, a double blind study but administered two dose levels of magnesium—100 mg and 365 mg. It is likely that the narrow therapeutic range (265 mg) or the absence of a non-intervention group, reflecting basic conditions, decreased the sensitivity of the study. Another study could also not demonstrate an effect after administration of 360 mg magnesium hydrochloride throughout pregnancy [21]. Blood pressure data were, however, only presented for the whole group. The statistically significant differences in birth weight etc (see below) were only present when patients not taking their magnesium tablets properly were excluded. Blood pressure data from this group were not reported.

    In summary, four studies from four different countries demonstrate that the supplementation with magnesium during pregnancy reduces the risk of pregnancy induced high blood pressure

    3.2. Prevention - other effects

    There are several studies where the effect of magnesium supplementation on other pregnancy complications than high blood pressure have been studied.

    In one DBRC study with 985 pregnant women, the supply of 360 mg magnesium aspartate significantly reduced the frequency of premature deliveries (< 258 days), and the number of children with a birth weight < 500 g [22]. The incidence of pre-eclampsia was significantly lower in the magnesium treated group. Another DBRC supplementation study comprised 568 pregnant women, allocated magnesium hydrochloride (365 mg) or placebo according to even/odd numbers of birth date [23]. The number of days spent in hospital due to pregnancy complications was 533 days in the magnesium group and 887 days in the placebo group. The number of women with pre-term labour, pre-term deliveries, and incomplete cervix closure was significantly lower in the magnesium group. The effect on pre-eclampsia could not be evaluated due to the small number of subjects with this complication.

    Contradictory findings were reported in a DBRC study on 374 pregnant women [15]. They received 375 mg magnesium/day in terms of magnesium-aspartate hydrochloride. No significant differences were found between the magnesium and placebo groups regarding blood pressure, foetal growth retardation, pre-eclampsia, preterm labour, birth weight, gestational age at delivery, or number of infants admitted to a special care hospital unit. The absence of any of these effects, quite in contrast to the previously cited study, could be due to an erroneous study design. The placebo group received a vitamin supplement containing 100 mg magnesium. Even this small dose might have influenced the investigated parameters, decreasing the difference between the magnesium high dose and the magnesium low dose groups to non-significant levels.

    The same endpoints as in the above two studies were investigated in an investigation in Italy [23]. 100 pregnant women participated in this DBRC study where 360 mg magnesium was administered daily. There were fewer hospitalisation days for the mother in the supplemented group as well as fewer premature births, and less underweight (< 2500 g) children.

    Similar findings were reported in a DBRC study on 240 magnesium citrate supplemented women and 250 controls [24]. The supplemented group had a significantly lower number of hospitalisation days for mothers due to threats of preterm labour, and higher birth weight for the babies. There was a tendency to lower rates of preterm labour and low birth weight (< 2500 g) in the supplemented group.

    In a small study on pregnant women, selected for risk of pre-mature labour, 22 women received 216 mg magnesium gluconate [25]. There were no differences in terms of preterm labour, gestational age at delivery or mean birth weights. There was no magnesium serum level increase in the supplemented group among the five women with preterm labour.

    Hypoxic, ischaemic encephalopathy (HIE) was studied in a sample of 4494 women with a low magnesium intake in food [26]. The supplementation was 64 mg magnesium/day, leading to a significantly higher level of red blood cell content of magnesium at delivery (1.75 vs 1.68 mmol/L). There was a significantly lower number of stillbirths in the magnesium supplemented group. There were no differences in gestational hypertension, premature onset of labour, or duration of pregnancy. There was a non-significant trend to a lower incidence of HIE in the magnesium treated group (15 vs 22 babies). If the supplemented and control groups were amalgamated, women with a red blood cell magnesium level below the median, had a sevenfold risk of having a baby with HIE. The authors concluded that due to the low incidence of HIE the study was statistically underpowered. The dose of magnesium in this study was quite low.

    Leg cramps is a common symptom in magnesium deficiency and they become more prevalent during pregnancy. One study comprised 74 pregnant women with leg cramps [27]. The supplementation in this DBPC study was 360 mg magnesium as citrate or lactate. There was a significantly larger reduction of subjectively experienced stress due to leg cramps in the supplemented group. Persisting symptoms the days after night cramps were also lower.

    4. Comments

    It is beyond doubt that magnesium plays an important role for the functioning of many different organs in the body, particularly muscles [2]. Regarding supplementation with magnesium during pregnancy to decrease the incidence of pregnancy complications, the picture is less clear. For all effects studied, there are positive as well as negative outcomes. The Cochrane report examined the different studies and classified some of those showing a beneficial effect as “low quality studies” [1]. Applying the latest scientific paradigms concerning study designs as in that review, will obviously discard older studies, performed according to principles used at that time although the data may be valid. On the other hand it is important to perform a quality assurance, both regarding conclusions how to deal with the supplementation problem today and as a background for future studies, There are, however, some basic errors in the Cochrane evaluation. One study was discarded as low quality as the assignment of supplementation/placebo was made according to the mothers’ birthday (odd-even) [21]. Even if this criterion does not fulfil the definition of DBRC as used today, the judgement is erroneous from a biological point of view. Birth dates, related to days, could not induce an error in relation to a biological effect. Furthermore, a study classified as good quality [15] administered magnesium also to the control group which is not a correct DBRC design and might have introduced dosage errors as discussed above.

    Apart from the strict scientific judgement of the studies as in Cochrane [1], there must also be a personalised interpretation of available data and the risk related to supplementation, weighing information regarding possible benefits. In contrast to medication e.g. with aspirin which has been tried in pre-eclampsia [28], magnesium is a natural substance and completely harmless except for occasional cases of diarrhoea. This implies that a decision to prescribe supplementation with magnesium should also take into account data from studies which may not be perfect according to modern standards. One should also weigh the tremendous savings that would result in terms of suffering of children and mothers as well as the costs for caretaking and treatment of PE and E. This being said, there is obviously a need for further studies, particularly in risk groups with high incidences of PE and E. With the data available and the lack of a risk supplementing with magnesium, one could, however, question whether a double-blind design in such studies is ethically correct.

    From a practical point of view, the absence of a consensus regarding magnesium treatment should not hinder the physician or maternal health care responsible to suggest a supplementation with magnesium, particularly to women with early symptoms such as leg cramps, oedema, and blurred vision.

    Conflict of Interest

    The author declares no conflict of interest in this article.

    [1] [ Parks J, Svendsen D, Singer P, et al. (2006) Morbidity and Mortality in People with Serious Mental Illness. Alexandria, VA: National Association of State Mental Health Program Directors Medical Directors Council.
    [2] [ Jones DR, Macias C, Barreira PJ, et al. (2004) Prevalence, severity, and co-occurrence of chronic physical health problems of persons with serious mental illness. Psychiatric Services 55: 1250-1257.
    [3] [ Sokal J, Messias E, Dickerson FB, et al. (2004) Comorbidity of medical illnesses among adults with serious mental illness who are receiving community psychiatric services. J Nervous Mental Disease 192: 421-427.
    [4] [ Cummings NA, O'Donohue W, Hays SC, et al. (2001) Integrated Behavioral Healthcare: Positioning Mental Health Practice with Medical/Surgical Practice. San Diego: Academic Press.
    [5] [ Regier DA, Goldberg ID, Taube CA (1978) The de facto US mental health services system: a public health perspective. Archives Gener Psych 35: 685-693.
    [6] [ Mental Health America (2007) Communicating About Health: A Mental Health America Survey of People with Schizophrenia and Providers. Alexandria, VA: Mental Health America.
    [7] [ Morden NE, Mistler LA, Weeks WB, et al. (2009) Health care for patients with serious mental illness: family medicine's role. J Am Board Family Med 22: 187-195.
    [8] [ Daub S (2014) Turning toward treating the seriously mentally ill in primary care. Fam Syst Health 32: 12-13.
    [9] [ Kisely S, Duerden D, Shaddick S, et al. (2006) Collaboration between primary care and psychiatric services: does it help family physicians? Canadian Family Physician 52: 876-877.
    [10] [ Robinson PJ, Reiter JT (2007) Behavioral Consultation and Primary Care. New York: Springer Science.
    [11] [ Altschuler J, Margolius D, Bodenheimer T, et al. (2012) Estimating a reasonable patient panel size for primary care physicians with team-based task delegation. Annals of Family Med 10: 396-400.
    [12] [ Muldoon L, Dahrouge S, Russell G, et al. (2012) How many patients should a family physician have? Factors to consider in answering a deceptively simple question. Healthcare Policy 7: 26-34.
    [13] [ Martin JL, McLean G, Park J, et al. (2014) Impact of socioeconomic deprivation on rate and cause of death in severe mental illness. BMC psychiatry 14: 261.
    [14] [ Reilly S, Planner C, Gask L, et al. (2013) Collaborative care approaches for people with severe mental illness. The Cochrane database of systematic reviews 11: CD009531.
    [15] [ Morrato EH, Newcomer JW, Kamat S, et al. (2009) Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 32: 1037-1042.
    [16] [ Nasrallah HA, Meyer JM, Goff DC, et al. (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Res 86: 15-22.
    [17] [ Frayne SM, Halanych JH, Miller DR, et al. (2005) Disparities in diabetes care: impact of mental illness. Archives Int Med 165: 2631-2638.
    [18] [ Haupt DW, Rosenblatt LC, Kim E, et al. (2009) Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 166: 345-353.
    [19] [ Zeidler Schreiter E (2013) Integration of behavioral health team and consulting psychiatrist into primary care enhances access to behavioral health care for low-income patients. Agency for Healthcare Research and Quality Health Care Innovations Exchange.
    [20] [ Zeidler Schreiter E, Pandhi N, Fondow M (2013) Access Community Health Centers (Access) Integrated Primary Care Consulting Psychiatry Toolkit.
    [21] [ Zeidler Schreiter E, Pandhi N, Fondow M, et al. (2013) Consulting psychiatry within an integrated primary care model. J Health Care Poor Underserved 24: 1522-1530.
    [22] [ van Orden ML, Deen ML, Spinhoven P, et al. (2015) Five-Year Mental Health Care Use by Patients Referred to Collaborative Care or to Specialized Care. Psychiatr Serv: appips201400238.
  • This article has been cited by:

    1. Esra Tuncer, Hülya Yardımcı, Potential Effects of Magnesium on Gestational Diabetes Mellitus, 2019, 1307-2048, 371, 10.21763/tjfmpc.609668
    2. G. B. Dikke, Elementary metabolomics and affordable tools for screening, diagnosis and treating hypomagnesemia in pregnancy, 2020, 2658-5790, 10, 10.21518/2079-701X-2020-3-10-16
    3. Benjamin Brown, Ciara Wright, Safety and efficacy of supplements in pregnancy, 2020, 78, 0029-6643, 813, 10.1093/nutrit/nuz101
    4. E. V. Mozgovaya, Justification of modern magnesium preparations for the prevention of obstetric complications, 2020, 2658-5790, 40, 10.21518/2079-701X-2020-13-40-49
    5. Katrina Beluska-Turkan, Renee Korczak, Beth Hartell, Kristin Moskal, Johanna Maukonen, Diane E. Alexander, Norman Salem, Laura Harkness, Wafaa Ayad, Jacalyn Szaro, Kelly Zhang, Nalin Siriwardhana, Nutritional Gaps and Supplementation in the First 1000 Days, 2019, 11, 2072-6643, 2891, 10.3390/nu11122891
    6. Kristína Podolská, Dana Mazánková, Mária Göböová, Význam a bezpečnosť suplementácie magnéziom v období tehotenstva.Suplementovať alebo nie?, 2024, 38, 12127973, 100, 10.36290/far.2024.016
  • Reader Comments
  • © 2015 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(5818) PDF downloads(1081) Cited by(1)

Article outline

Figures and Tables

Figures(4)  /  Tables(1)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog